CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.
  
  LEARNING OBJECTIVES

  • Appraise published research findings on optimal disease management approaches for patients with biochemical recurrence after local treatment for prostate cancer, and counsel appropriate individuals regarding the potential benefits of systemic therapy.
  • Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic prostate cancer, and apply this information in the discussion of nonresearch treatment options.
  • Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer, and effectively integrate these strategies into clinical management algorithms.
  • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with metastatic castration-resistant prostate cancer (mCRPC), considering age, comorbidities, prior therapeutic exposure and other clinical and biological factors.
  • Assess the available research database supporting the use of PARP inhibitors as monotherapy or in combination with androgen receptor pathway inhibitors for patients with mCRPC harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into current clinical management algorithms.
  • Appreciate available Phase III data documenting the efficacy of PSMA-targeted radioligand therapy for patients with PSMA-positive mCRPC, and consider the current and future clinical role of this strategy.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Video Program: Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 2.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
  Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/AUA2024/Prostate/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Rahul Aggarwal, MD
  Professor of Medicine and Thomas Perkins Distinguished Professor of Cancer Research
  Director, Genitourinary Medical Oncology
  University of California, San Francisco
  Department of Medicine
  Division of Hematology/Oncology
  Associate Director for Clinical Research
  UCSF Helen Diller Family Comprehensive Cancer Center
  San Francisco, California
  
  No relevant conflicts of interest to disclose.
  
  Adam S Kibel, MD
  Chair, Department of Urology
  DiNovi Family Distinguished Chair in Urology
  Brigham and Women’s Hospital
  Elliott Carr Cutler Professor of Surgery
  Harvard Medical School
  Boston, Massachusetts
  
  Advisory Committees: Janssen Biotech Inc, Pfizer Inc, ProFound Therapeutics, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: Bristol Myers Squibb, Candel Therapeutics.
  
  Laurence Klotz, CM, MD
  Professor of Surgery, University of Toronto
  Sunnybrook Chair of Prostate Cancer Research
  Chair, Council for Academic Freedom at University of Toronto (CAFUT)
  Member, Order of Canada
  Sunnybrook Health Sciences Centre
  Toronto, Ontario, Canada
  
  No relevant conflicts of interest to disclose.
  
  Sandy Srinivas, MD
  Professor of Oncology
  Clinical Research Leader, GU Oncology
  Stanford University
  Stanford, California
  
  Advisory Committees: Aveo Pharmaceuticals, Eisai Inc, Janssen Biotech Inc, Novartis, Seagen Inc; Contracted Research: Bristol Myers Squibb, Merck, Novartis, Regeneron Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Pfizer Inc.
  
  CONSULTING CLINICAL INVESTIGATORS — Jason Hafron, MD — Advisory Committees: Astellas, Dendreon Pharmaceuticals Inc, Immunis.AI, Janssen Biotech Inc, Lipella Pharmaceuticals Inc (study/trial), Pfizer Inc; Consulting Agreements: Lilly, Lynx Dx, Myovant Sciences, Myriad Genetic Laboratories Inc, Photocure, Promaxo, Tolmar; Contracted Research: Astellas, Dendreon Pharmaceuticals Inc, Janssen Biotech Inc, Lipella Pharmaceuticals Inc, miR Scientific, Myovant Sciences, Myriad Genetic Laboratories Inc, Nucleix, Pfizer Inc; Patent without Royalty: Lipella Pharmaceuticals Inc; Speakers Bureaus: Amgen Inc, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Janssen Biotech Inc, Lantheus, Merck, Myriad Genetic Laboratories Inc, Pfizer Inc, PROCEPT BioRobotics, Tolmar. David S Morris, MD — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Pfizer Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Clovis Oncology, Janssen Biotech Inc, Merck, Pfizer Inc.
  
  MODERATOR
  Elisabeth I Heath, MD
  Associate Center Director, Translational Sciences
  Chair, Genitourinary Oncology Multidisciplinary Team
  Professor of Oncology and Medicine
  Hartmann Endowed Chair for Prostate Cancer Research
  Director, Prostate Cancer Research
  Karmanos Cancer Institute
  Wayne State University School of Medicine
  Detroit, Michigan
  
  Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Sanofi; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Sanofi; Contracted Research: Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics Inc, Bristol Myers Squibb, Calithera Biosciences, Caris Life Sciences, Corcept Therapeutics, Corvus Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, F Hoffmann-La Roche Ltd, Five Prime Therapeutics Inc, Fortis Therapeutics, Gilead Sciences Inc, GSK, Harpoon Therapeutics, Infinity Pharmaceuticals Inc, iTeosTherapeutics, Janssen Biotech Inc, Merck, Mirati Therapeutics Inc, Modra Pharmaceuticals, MSD, Novartis, Oncolys BioPharma, Peloton Therapeutics Inc, a wholly-owned subsidiary of Merck & Co Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, POINT Biopharma, Seagen Inc; Honoraria/Paid Travel: Astellas, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Sanofi, Seagen Inc; Speakers Bureau: Sanofi; Nonrelevant Financial Relationship: Calibr.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Merck.
  
  Release date: May 2024
  Expiration date: May 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.